Eton Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Financial statements are unaudited; amounts below are in millions of dollars unless noted. Eton develops, acquires, and commercializes rare-disease medicines. Its commercial products include ALKINDI SPRINKLE, Carglumic Acid, and Betaine Anhydrous; it also reported four late-stage product candidates.
Key financial results
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net revenue | $12.0 | $7.4 | $17.3 | $9.5 |
| Gross profit | $9.7 | $4.6 | $13.0 | $5.9 |
| Gross margin | 80.7% | 62.7% | 75.3% | 62.3% |
| Operating income (loss) | $3.9 | $(1.3) | $1.3 | $(6.4) |
| Net income (loss) | $4.6 | $(1.6) | $1.9 | $(6.9) |
| Diluted EPS | $0.18 | $(0.06) | $0.07 | $(0.28) |
- Revenue rose approximately 63% year over year in Q2 and 81% for the first half. Product sales and royalties increased to $6.5 million in Q2 and $11.8 million for the first half, primarily on higher ALKINDI SPRINKLE and Carglumic Acid sales. Licensing revenue was $5.5 million in Q2, including the sale of Eton’s retained royalty interests in three products to Azurity.
- Q2 other income included an $0.8 million break-up fee from an asset acquisition auction in which Eton was not the winning bidder. Six-month net income also includes this fee.
- Cash provided by operations was $5.6 million for the first half, versus $3.7 million a year earlier. Investing cash flow was zero, compared with $0.8 million used in 2022; financing used $0.3 million in both periods. Cash increased $5.3 million to $21.6 million.
- At June 30, cash was $21.6 million, current assets $26.3 million, current liabilities $9.6 million, and working capital approximately $16.7 million. Total assets were $30.9 million.
- Debt consisted of a SWK loan: $1.5 million classified current and $4.6 million long-term, net of discount, at June 30. Scheduled principal and interest payments totaled $7.6 million through 2024, including $1.2 million for the remainder of 2023. The loan is secured and includes covenants; Eton was discussing an amendment to replace LIBOR with an alternate reference rate.
Changes, outlook, and risks
- Compared with Q2 2022, stronger product sales and lower cost of sales drove higher gross profit and a swing to operating and net income. First-half R&D expense declined year over year, while Q2 R&D increased, mainly due to a $0.45 million ET-600 registration-batch milestone accrual. G&A was broadly flat year over year for the first half.
- Management said existing cash, product revenue, and milestone payments expected in 2023 should fund operating and capital needs for at least 12 months from the filing date. This depends on sales, spending control, and other assumptions; Eton cautioned it may need additional capital, which may not be available on acceptable terms and could dilute shareholders. Delays in development, sales growth, regulatory approvals, or financing could require it to scale back or discontinue operations.
- Revenue and receivables are concentrated: AnovoRx represented 63.5% of first-half 2023 revenue and 84.2% of net receivables at June 30. The company relies on a small number of third-party suppliers, creating manufacturing interruption risk.
- Bausch Health discontinued sales of Alaway Preservative Free effective March 24, 2023; this may affect potential royalties. Eton also disclosed possible product-development and commercial milestone obligations, including for ET-600, ZENEO hydrocortisone, and ALKINDI SPRINKLE.
- No formal financial guidance was provided. The filing reported no material pending or threatened litigation, no off-balance-sheet transactions, and effective disclosure controls. Management emphasized that interim results are not necessarily indicative of full-year results.
Important facts for investors to verify
- Whether growth in ALKINDI SPRINKLE and Carglumic Acid sales is sustained, and how product-level economics and margins develop.
- Whether the Azurity royalty-interest sale and the $0.8 million break-up fee are nonrecurring; assess earnings excluding these items.
- Cash conversion and working-capital movements, particularly rising receivables and the AnovoRx customer concentration.
- Timing and terms of SWK debt repayments, covenant compliance, and the proposed replacement for LIBOR.
- Regulatory, manufacturing, and funding progress for late-stage candidates and the associated milestone commitments.